Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. J Thorac Oncol. 2014; 9: e21-e23.Ren S, Hirsch FR, Varella-Garcia M, et al. Atypical negative ALK break-apart FISH harboring a crizotinib- responsive ALK rearrangement in...
reported a single case of non-small cell lung cancer (NSCLC) with both ALK rearranged and amplified tumor cells detected by fluorescence in situ hybridization (FISH). The immunohistochemistry (IHC) analysis was negative, which for them questions the use of an ALK IHC-based prescreening algorithm ...
Computed tomography revealed a mass in the left upper lung of a nonsmoking 60-year-old woman. Pathological findings using resected tissue were consistent with PPC...关键词: Smoking history, Predictor, Pemetrexed, Maintenance therapy, Non-small cell lung cancer ...
Reply to the letter to the editor ' ALK FISH rearranged and amplified tumor with negative immunohistochemistry: a rare and challenging case concerning ALK status screening in lung cancer' by Uguen et al. 来自 国家科技图书文献中心 喜欢 0 阅读量: 56 作者:...
to be associated with perceived coercion; negative perceived pressures were linked to younger age, involuntary status, seclusion, and positive schizophrenic symptoms; while procedural injustice was associated with younger age, involuntary status, fewer negative schizophrenic symptoms, and cognitive impairment....
Drug resistance remains an elusive problem in cancer therapy, particularly for novel targeted therapies. Much work is focused upon the development of an arsenal of targeted therapies, towards oncogenic driver genes such as ALK-EML4, to overcome the inevi
Human tissue was treated with RNAse treatment in the negative control (right) and showed no detected signal. CoQFISH detects Eml4-Alk fusion transcripts. Differential interference contrast (DIC) shows human non-small cell lung cancer tissue structure on the right. Co-localized signal from Eml4 (...
Progression-free survival (PFS), duration of response, and objective response rate were compared between intention-to-treat (ITT) and biomarker-evaluable populations, and plasma ALK-positive and plasma ALK-negative subpopulations. Results In the ITT population (303 patients; alectinib, 152; crizotinib...
BackgroundAnaplastic lymphoma kinase (ALK) fusion events account for 3 to 7% of genetic alterations in patients with nonsmall cell lung cancer (NSCLC). This study aimed to explore the landscape of ALK fusion-positive and ALK fusion-negative in a large cohort of NSCLC patients. MethodsThe ...